Merrimack Pharmaceut (MACK) 5.82 $MACK Merrimack (MACK):

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 7:20 AM

Merrimack Pharmaceut (MACK) 5.82 $MACK

Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 5.82 (+0.02), IRWD: 13.94 (-0.19), LLY: 83.18 (+0.29), EXEL: 9.27 (+0.09)

Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:45PM CDT
Celgene's (CELG) Revlimid gained label expansion in the EU; it can now be used for the treatment of adults with relapsed or refractory mantle cell lymphoma.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), CELG: 114.69 (+2.50)

ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
ZIOPHARM (ZIOP) announced the death of a patient in a phase I study on Ad-RTS-hIL-12 in the treatment of recurrent or progressive GBM or grade III malignant glioma.
MACK: 5.82 (+0.02), ZIOP: 5.06 (+0.20), INVA: 13.04 (+0.17), XON: 27.38 (+2.05)

Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 9:36AM CDT
Gilead (GILD) received a Notice of Compliance from Health Canada for Epclusa for the treatment of adults with genotype 1-6 chronic HCV infection.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch)

Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 8:51AM CDT
Ultragenyx (RARE) announced top-line data from a pivotal phase III study on rhGUS for the treatment of mucopolysaccharidosis 7.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), RARE: 63.53 (+0.25), PFE: 37.31 (+0.42)

Bayer Expands Drug Discovery Collaboration with X-Chem
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 3:06PM CDT
Bayer (BAYRY) inked an expanded global drug discovery deal with X-Chem, Inc. across multiple therapeutic areas and target classes.
MACK: 5.82 (+0.02), FCSC: 1.02 (-0.07), BMY: 76.19 (+1.38)

BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 12%
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:15AM CDT
BioDelivery Sciences International, Inc.(BDSI) shares rose 12% on the day.
MACK: 5.82 (+0.02), BDSI: 2.41 (-0.14)

CytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:07AM CDT
CytRx (CYTR) announced unfavorable initial results from a phase III study on aldoxorubicin in patients with relapsed or refractory soft tissue sarcomas.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), GWPH: 96.11 (+1.79), CYTR: 0.60 (-0.05)

Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 4:46AM CDT
Juno's (JUNO) shares were up in after-market hours following the lifting of the clincal hold on the company's pivotal ROCKET study.
MACK: 5.82 (+0.02), BLUE: 56.30 (-0.88), KITE: 57.03 (+0.40), JUNO: 30.86 (-0.07)

Merrimack Stock Up on Fast Track Status for Seribantumab
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:22PM CDT
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
MACK: 5.82 (+0.02), INVA: 13.04 (+0.17), GWPH: 96.11 (+1.79), UTHR: 125.08 (+4.07)

Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 5.82 (+0.02), ALNY: 71.80 (+3.72), GERN: 2.71 (+0.03), CYTR: 0.60 (-0.05)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), LGND: 138.53 (+3.65), ACOR: 25.13 (-0.15)

Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 5.82 (+0.02), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), PFE: 37.31 (+0.42)

Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
PR Newswire - Mon Jun 06, 6:30AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MACK: 5.82 (+0.02)

Merrimack/Baxalta Start Study on Colorectal Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri May 20, 1:37PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) and Baxalta Incorporated (BXLT) announced that the companies have initiated a phase I clinical study on pipeline candidate, MM-151.
MACK: 5.82 (+0.02), ABT: 45.29 (+0.54), PFE: 37.31 (+0.42), BXLT: 46.02 (-0.18)

Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
PR Newswire - Thu May 19, 6:05AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers. Merrimack's first-of-its-kind basket study will use a combination of genetic and nongenetic biomarkers to match patients to appropriate novel combinations of investigational drug regimens based on their cancer's molecular signature. This approach is expected to enable more than 95 percent of eligible patients to qualify for enrollment to one of the investigational arms of the study. Merrimack utilized its systems biology approach to identify the biomarkers and selection criteria of the study.
MACK: 5.82 (+0.02)

Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
PR Newswire - Thu May 19, 6:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the initiation of a Phase 1 clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study advances the development path for ONIVYDE.
MACK: 5.82 (+0.02), BXLT: 46.02 (-0.18)

Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Wed May 18, 4:10PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions.
MACK: 5.82 (+0.02)

Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
PR Newswire - Tue May 17, 3:05PM CDT
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today presented an expanded analysis of its Phase 2 study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer. Top line results from this study were announced in 2014. The final analysis, as well as a poster on Merrimack's investigational companion diagnostic for seribantumab, were presented this week at the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, in Miami, Florida.
MACK: 5.82 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NSF Backs New Space Projects: Cooling & Drug Delivery

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

NORD Honors Innovators Shaping Rare Disease Treatment

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

New Podcast by Paralyzed Veterans of America Offers Unique Insights

Empowering Veterans Through Storytelling Some stories don't just rattle around in your headphones—they stick with you. The 'Voices of PVA' podcast, launched by Paralyzed Veterans of America, aims to do exactly that. It's not just a podcast; it's a platform where voices of veterans and people with spinal cord injuries like MS and ALS aren't just heard, they're amplified....

Rise Treatment Center Launches in Vegas for Teens

Las Vegas Debuts Rise Adolescent Treatment Center Imagine being a parent in Las Vegas, staring at the daunting task of finding genuine help for your teenage kid just entering those rebellious years. The choices usually feel sparse and lacking. But on August 13, 2026, a shimmer of hope illuminated the landscape with the opening of Rise Adolescent Treatment Center. It’s a...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

Unicycive's Legal Turmoil: Opportunity for Investor Action

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Dr. David Lifschutz Honored for Psychiatry Innovation

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Starr Conspiracy Unveils AI Tool for B2B Tech Firms

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...